Evidence map›Paper›PMID 30581339›Full record

ArticleJournal of medical biochemistry2018

Bojana B Ilic, Jadranka A Antic, Jovana Z Bankovic, Ivana T Milicevic, Gordana S Rodic, Dusan S Ilic, Cane D Tulic, Vera N Todorovic, Svetozar S Damjanovic

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical biochemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Expression and clinical significance of PDK family in breast cancer based on data mining.International journal of clinical and experimental pathology · 2021
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Bojana B IlicClinic for Endocrinology, Diabetes and Metabolic Diseases, Medical School, University of Belgrade, Department of Neuroendocrine Tumors and Hereditary Cancer Syndromes, Belgrade, Serbia.
Jadranka A AnticClinic for Endocrinology, Diabetes and Metabolic Diseases, Medical School, University of Belgrade, Department of Neuroendocrine Tumors and Hereditary Cancer Syndromes, Belgrade, Serbia.
Jovana Z BankovicClinic for Endocrinology, Diabetes and Metabolic Diseases, Medical School, University of Belgrade, Department of Neuroendocrine Tumors and Hereditary Cancer Syndromes, Belgrade, Serbia.
Ivana T MilicevicClinic for Endocrinology, Diabetes and Metabolic Diseases, Medical School, University of Belgrade, Department of Neuroendocrine Tumors and Hereditary Cancer Syndromes, Belgrade, Serbia.
Gordana S RodicClinic for Endocrinology, Diabetes and Metabolic Diseases, Medical School, University of Belgrade, Department of Neuroendocrine Tumors and Hereditary Cancer Syndromes, Belgrade, Serbia.
Dusan S IlicClinic for Endocrinology, Diabetes and Metabolic Diseases, Medical School, University of Belgrade, Department of Neuroendocrine Tumors and Hereditary Cancer Syndromes, Belgrade, Serbia.
Cane D TulicClinic for Urology, Medical School, University of Belgrade, Belgrade, Serbia.
Vera N TodorovicInstitute for Histology and Embryology, School of Medicine of Military Medical Academy, University of Defense, Belgrade, Serbia.
Svetozar S DamjanovicClinic for Endocrinology, Diabetes and Metabolic Diseases, Medical School, University of Belgrade, Department of Neuroendocrine Tumors and Hereditary Cancer Syndromes, Belgrade, Serbia.
Military Medical Academy · RSUniversity of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSporadic clear-cell renal cell carcinoma (ccRCC) is associated with mutations in the VHL gene, upregulated mammalian target of rapamycin (mTOR) activity and glycolytic metabolism. Here, we analyze the effect of VHL mutational status on the expression level of mTOR, eIF4E-BP1, AMPK, REDD1, and PDK3 proteins.

methodsTotal proteins were isolated from 21 tumorous samples with biallelic inactivation, 10 with monoallelic inactivation and 6 tumors with a wild-type VHL (wtVHL) gene obtained from patients who underwent total nephrectomy. The expressions of target proteins were assessed using Western blot.

resultsExpressions of mTOR, eIF4EBP1 and AMPK were VHL independent. Tumors with monoallelic inactivation of VHL underexpressed REDD1 in comparison to wtVHL tumors (P = 0.042), tumors with biallelic VHL inactivation (P < 0.005) and control tissue (P = 0.004). Additionally, REDD1 expression was higher in tumors with VHL biallelic inactivation than in control tissue (P = 0.008). Only in wt tumor samples PDK3 was overexpressed in comparison to tumors with biallelic inactivation of VHL gene (P = 0.012) and controls (P = 0.016). In wtVHL ccRCC, multivariate linear regression analysis revealed that 97.4% of variability in PDK3 expression can be explained by variations in AMPK amount.

conclusionExpressions of mTOR, eIF4EBP1 and AMPK were VHL independent. We have shown for the first time VHL dependent expression of PDK3 and we provide additional evidence that VHL mutational status affects REDD1 expression in sporadic ccRCC.

Indexed as

clear-cell renal cell carcinomamammalian target of rapamycinpyruvate dehydrogenase kinase 3regulated in development and DNA damage responsesVHL gene

Identifiers

PMID30581339
PMCPMC6294108
OpenAlexW2744370942

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.